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Abstract: Glembatumumab vedotin (CDX-011, GV) is a fully human Immunoglobulin G2 monoclonal
antibody directed against glycoprotein NMB coupled via a peptide linker to monomethyl auristatin
E (MMAE), a potent cytotoxic microtubule inhibitor. This phase II study evaluated the overall
response rate and safety of GV, glycoprotein NMB (GPNMB) expression, and survival in patients
with metastatic uveal melanoma. Eligible patients with metastatic uveal melanoma who had not
previously been treated with chemotherapy received GV 1.9 mg/kg every three weeks. The primary
endpoint was the objective response rate (ORR). Secondary endpoints included GPNMB expression,
progression-free survival (PFS), overall survival (OS), and toxicity analysis. GPNMB expression
was assessed pre- and post-treatment via immunohistochemistry for patients with available tumor
tissue. Out of 35 patients who received treatment, two patients had confirmed partial responses
(PRs; 6%), and 18 patients had a stable disease (SD; 51%) as the best objective response. 38% of the
patients had stable disease >100 days. The grade 3 or 4 toxicities that occurred in two or more patients
were neutropenia, rash, hyponatremia, and vomiting. The median progression-free survival was
3.1 months (95% CI: 1.5–5.6), and the median overall survival was 11.9 months (95% CI 9.0–16.9) in
the evaluable study population. GV is well-tolerated in metastatic uveal melanoma. The disease
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control rate was 57% despite a low objective response rate. Exploratory immune correlation studies
are underway to provide insight into target saturation, combination strategies, and antigen release.
Keywords: uveal melanoma; glembatumumab vedotin; phase II; clinical trial

1. Significance
Metastatic uveal melanoma is an orphan disease with no FDA-approved disease-specific treatment
options. Immunotherapy and targeted therapy are not as effective as in cutaneous melanoma
because of the differences in disease biology and clinical characteristics. This phase II trial of
glembatumumab vedotin in patients with metastatic uveal melanoma showed a 57% disease control
rate (complete response (CR), partial response (PR), and stable disease (SD)) despite a low objective
response rate (6%). Treatment was well-tolerated except for neutropenia, which was managed with
granulocyte-macrophage colony-stimulating factor (GM-CSF).
2. Background
Uveal melanoma is the most common primary intraocular malignancy in adults and constitutes
3.1% of all melanoma diagnoses. In the United States, the incidence of uveal melanoma has remained
stable at 5.1 per million for the past 50 years in contrast to the rising incidence of cutaneous
melanoma [1,2]. Though treatment of the primary tumor is highly efficacious, approximately half of
the 3000 patients who are diagnosed annually with uveal melanoma will develop metastatic disease [3].
Unfortunately, many of the therapeutic advances that have revolutionized the treatment of cutaneous
melanoma have not effectively translated to the uveal melanoma population [4].
The disparity between cutaneous and uveal melanoma is likely attributable to differences in their
biology. Whereas cutaneous melanoma is characterized by a UV-mediated high mutation burden and a
high incidence of activating mutations in the BRAF protein, uveal melanoma carries a low mutational
burden, no UV mutation signature, and a rare occurrence of BRAF mutations. Early canonical activating
mutations in the MAPK pathway in GNAQ or GNA11 have not led to the successful targeting of the
MAPK pathway [5,6]. Similarly, immunotherapies with checkpoint inhibitors have not demonstrated
the same efficacy as in cutaneous melanoma [7]. In previously published work in metastatic uveal
melanoma, PD-L1 expression in these tumors was found to be low-to-absent in the majority of cases,
which may account for the low response rates to checkpoint blockades [8,9]. This is in contrast to the
notable expression of other checkpoint molecules like indoleamine 2, 3-dioxygenase (IDO) and the
T cell Ig and ITIM domain (TIGIT) [10]. Regrettably, clinical experience with these latter checkpoint
modulators for uveal melanoma is not known. As such, uveal melanoma is left without a standard of
care for metastatic disease, and this lack of effective treatment contributes to a median of approximately
six-to-thirteen month overall survival rates for patients with metastatic uveal melanoma [11].
Glycoprotein NMB (GPNMB) is a transmembrane protein whose overexpression promotes the
invasion and metastasis of cancer cells and is expressed at high levels in uveal melanoma. In preclinical
studies, 86% of uveal melanoma specimens demonstrated positive immunohistochemistry (IHC)
staining for GPNMB, though with variable intensity [12]. Glembatumumab vedotin (GV) is a fully
humanized monoclonal antibody directed against GPNMB that is coupled to the potent cytotoxic
microtubule inhibitor monomethyl auristatin E (MMAE) [13]. The proposed mechanism of action is
that upon the binding of GPNMB, the complex is internalized, MMAE is released in the lysosome,
and tumor cell death occurs as a result of microtubule-inhibition mediated apoptosis. In mouse
xenografts with the GPNMB-expressing melanoma cell lines SK-Mel-2 and SK-Mel-5, treatment with
GV was found to induce the complete regression of tumors [14–16].
Given these promising preclinical results and the biological plausibility of the anti-tumor
mechanism, this phase II study was undertaken to determine the effect of single-agent GV on
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the overall response of patients with metastatic uveal melanoma while also determining the clinical
safety, pharmacodynamics, and GPNMB expression of tumors.
3. Methods
3.1. Study Design
This single-arm, open label phase II trial assessed the efficacy of a single agent, GV, in patients
with metastatic uveal melanoma who had not previously been treated with chemotherapy. Enrollment
began in January of 2016 and concluded in September of 2017. Seven institutions participated in the trial.
All eligible patients were treated with the investigational therapy after obtaining informed consent.
3.2. Patient Selection
Patients were considered eligible if they had a histologically or cytologically confirmed metastatic
uveal melanoma. Patients with a previous history of uveal melanoma in whom the histologic or
cytologic diagnosis was not possible were also allowed at the discretion of the treating investigator.
Eligible patients had to be aged greater than 18 years, an Eastern Cooperative Oncology Group (ECOG)
performance status of 2 or better, a life expectancy longer than three months, a measurable disease by
RECIST version 1.1, adequate organ function, and treatment-naive for chemotherapy. Patients may
have received radiation, immunotherapy, and liver-directed or targeted therapy, but all treatment must
have been completed 28 days before study drug treatment and prior treatment-related toxicities had
to be CTCAEv4 (Common Terminology Criteria for Adverse Events version 4) grade ≤ 1. Both men
and women and members of all races and ethnic groups were eligible. The protocol and amendments
were approved by the Central Institutional Review Board for the National Cancer Institute under the
study ID of 9855. All participants of the study provided written informed consent before initiating
study procedures.
3.3. Dosing Regimen
All eligible patients were intravenously treated with GV at a dose of 1.9 mg/kg actual body weight
every three weeks as outpatients. GV was prepared by dilution in 5% dextrose and administered as
a 90-min infusion without premedication. Patients who experienced grade 3 toxicity were treated
with reduced doses of 1.3 mg/kg every three weeks and then, if recurrent, at 1 mg/kg every three
weeks. An algorithm for the management of hypersensitivity or allergic reactions was provided
to investigators.
3.4. Response Criteria
Investigator-determined tumor response was radiographically measured every six weeks from
treatment initiation using RECIST version 1.1 [17].
3.5. Toxicity Capture
Clinical and laboratory assessments were conducted at baseline and every three weeks for
up to 30 days following the off-treatment date. Adverse events were graded according to the
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0
(https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40).
3.6. Statistical Analysis
The primary end point was the overall response rate. Secondary end points included overall
survival, progression-free survival, clinical safety, tolerability, and pharmacodynamics changes in
GPNMB expression by IHC. Patients who received at least one dose of therapy or who experienced
objective disease progression during the first cycle of therapy were evaluable for the primary end point
and the secondary end points.
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A single arm, non-randomized design using Simon’s two stage design was used to evaluate
the primary end point. In this design, 18 patients are enrolled in the first stage, and if at least one
response is observed in this first stage, up to 14 additional patients are enrolled in the second stage.
Assuming 15% of metastatic uveal melanoma samples do not express GPNMB and therefore would
not be expected to respond, this study targeted an objective response rate (ORR) of 20% compared to
the historical reference ORR of 5%.
Toxicity was reported by type, frequency, and severity according to the NCI Common Toxicity
Criteria v4.0. All patients who received any amount of study drug was evaluable for toxicity.
Progression-free survival (PFS) and overall survival (OS) survival curves were calculated using
the Kaplan–Meier method. The median PFS and OS were reported with 95% confidence intervals.
3.7. Correlative Analysis
Correlative analysis included changes in GPNMB expression via IHC after 1 cycle of GV and a
correlation of development of skin rash in cycle 1 with response.
3.8. Immunohistochemistry
GPNMB expression was assessed via IHC at Mosaic Laboratories (Lake Forest, CA, USA).
The GPNMB (goat polyclonal) IHC assay was designed and validated to be compatible with CLIA
guidelines for “homebrew” class I test validation. The procedure for the IHC analysis of GPNMB (goat
polyclonal) was performed using automated detection at room temperature (RT) on the Dako Link
Autostainer 48. Specimens were sectioned at 3–5-micron thickness, mounted onto positive-charged
glass slides, dried, baked, deparaffinized, and rehydrated. Tissue sections then underwent pretreatment
using a FLEX Target Retrieval Solution at a high pH (1×, Dako, Catalog# K8004 or S2367, Agilent,
Santa Clara, CA, USA) for 40 min in the PT Link (Dako) set to 97 ◦ C. Slides were cooled to 65 ◦ C
inside the PT Link, removed, and immediately placed into a FLEX Wash Buffer (Dako, Catalog# K8007)
for up to 5 min before placing onto the autostainer. Once the autostainer procedure was initiated,
the slides were rinsed with a buffer immediately and after each of the following steps: (1) Incubate with
anti-GPNMB antibody or isotype negative control for 30 min; (2) detect with rabbit anti-goat (Vector
Laboratories, Burlingame, CA, USA) for 15 min and PowerVision poly AP anti-rabbit IgG for 15 min
(rinse for 5 min in a buffer); and (3) stain with a Warp Red buffer solution (BioCare Medical, Concord,
CA, USA) for 7 min each. Upon the completion of the staining procedure, slides were counterstained
with hematoxylin (Dako) for 2 min followed by a rinse in distilled water, a rinse with a wash buffer
for 5 min, and then another rinse in distilled water. Coverslip mounting occurred offline using an
automated cover slipper in accordance with Mosaic Laboratories’ standard operating procedures.
Staining was evaluated by a pathologist, and the evaluation of reactivity involved a combination
of the following: the cellular localization of staining, staining intensity, subcellular localization, and the
percentage of cells staining in the primary component of the tissue type of interest. The GPNMB (goat
polyclonal) assay was evaluated on a semi-quantitative scale, and the percentage of cells staining at
each of the following four levels was recorded as 0 (unstained), 1+ (weak staining), 2+ (moderate
staining), and 3+ (strong staining). The interpretation was performed within the tumor cells of the
entire tissue. All tumor cells were considered in the score. A total positive score (percent positive) was
derived using variety of magnifications (4×, 10×, and 20×).
4. Results
4.1. Demographics
Between January 2016 and September 2017, 37 patients were enrolled in the study. The Early Drug
Development Opportunity Program (EDDOP) sites were added in August 2016. EDDOP contributed
four patients to this effort. Baseline demographics are presented in Table 1. The site of metastases
was predominantly the liver, followed by the lung, the lymph node, deep soft tissue, bones, skin,
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and subcutaneous tissue. The seventh edition M-stage AJCC uveal melanoma – which designates M1a
for tumors 3 cm or smaller, M1b for tumors 3–8 cm, and M1c for tumors greater than 8 cm—was used.
The enrolled population was balanced for M-stage.
Table 1. Baseline patient characteristics.
Characteristics

No. of Patients

Age in years
Median
Range

62
29–79

Gender
Male
Female

18
17

51
49

Performance Status (ECOG)
0
1

26
9

74
26

M-Stage *
M1a
M1b
M1c

16
12
7

46
34
20

17
3
15

48
9
43

14
9
6
5
2
1 each

40
26
17
17
14
6
3

Sites of Metastasis **
Liver only
Extrahepatic only
Both liver and extraHepatic
Extrahepatic sites
Lung
Lymph node
Bones
Peritoneum/Soft tissue
Subcutaneous
Muscle
All other sites ***

%

Abbreviation: ECOG, Eastern Cooperative Oncology Group. * 7th edition AJCC M-stage uveal melanoma: M1a for
tumors 3 cm or smaller, M1b for 3–8 cm tumors, and M1c for tumors greater than 8 cm. The enrolled population was
balanced for M-stage. ** The most common site of metastasis was the liver. Patients could have more than one site
of metastasis. *** Other extrahepatic sites were the brain, the orbit, the thyroid, the heart, the stomach, the spleen,
the gallbladder, the adrenal gland, and the kidney.

4.2. Efficacy
Of 37 patients enrolled in the study, 35 were assigned to treatment with GV. One participant
withdrew consent before starting the treatment, and another was ineligible to receive treatment due to
elevated liver transaminases. There were two confirmed PRs (6%) via RECIST 1.1 in patients with
M1b and M1c disease in the liver, and there were no CRs. An SD was seen in 51% (n = 18) as the best
overall response in the study, while 40% of the patients experienced the progression of disease (PD)
(n = 14). One patient did not have a post-baseline tumor assessment after being removed from study
due to an adverse event in cycle 1 (grade 4 neutropenia). Another patient without a post-baseline
tumor assessment died during cycle 1 due to PD and was counted in the PD rate. The disease control
rate—defined as the sum of CR, PR, and SD—was 57% (n = 20). Efficacy is presented in Figure 1 as
a waterfall plot and in Table 2 as text. The median duration of response was 8.6 months (263 days
with a range of 149–377 days). Three patients had new lesions appear at their first tumor assessments,
thus qualifying these responses as the progression of disease despite reductions in target lesion(s).
An SD lasting longer than 100 days was noted in 34% (n = 12) of the total study population, representing
the majority of patients with an SD. The median duration of the SD across the study was 4.8 (147 days)
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majority of patients with an SD. The median duration of the SD across the study was 4.8 (147 days)

months. Figure 2 shows comparative computerized tomography images of metastatic uveal melanoma
months. Figure 2 shows comparative computerized tomography images of metastatic uveal
tumors before and in response to GV treatment.
melanoma tumors before and in response to GV treatment.

Figure 1. Best overall response of target lesions to glembatumumab vedotin. For each evaluable
Figure
1. Best overall response of target lesions to glembatumumab vedotin. For each evaluable patient,
patient, the best response (defined by shrinkage in RECIST target lesions) is indicated (n = 32). Dark
the best response (defined by shrinkage in RECIST target lesions) is indicated (n = 32). Dark blue bars
blue bars indicate the patients with partial response, light blue columns show the patients who had
indicate the patients with partial response, light blue columns show the patients who had stable disease,
stable disease, and red columns represent patients with the progression of disease. Asterisks indicate
and red
columns represent patients with the progression of disease. Asterisks indicate the patients who
the patients who had appearance of new lesions at the first tumor evaluation. Of the 3 patients not
had appearance
of newdied
lesions
at the
tumor
Of the of
3 patients
not shown,
one patient
shown, one patient
during
cyclefirst
1 due
to theevaluation.
clinical progression
disease without
post-baseline
died during
cycle 1 dueand
to another
the clinical
progression
of disease
withoutand
post-baseline
tumor assessment,
was removed
for grade
4 neutropenia
acute kidneytumor
injuryassessment,
during
and another
for grade
4 neutropenia
and acute kidney
injury
during
1 and did
cycle 1 was
and removed
did not have
post-baseline
tumor assessment.
The third
patient
had cycle
a complete
disappearance
of target
lesion(s)
at the first
tumor
was noted to have
not have
post-baseline
tumor
assessment.
Thepost-baseline
third patient
hadassessment
a completebut
disappearance
of target
new
tumors
elsewhere,
so
the
best
response
was
classified
as
the
progression
of
disease.
This
patient
lesion(s) at the first post-baseline tumor assessment but was noted to have new tumors elsewhere,
notresponse
have tumor
measurements
into the database
and was
therefore
notdid
included
in the
so thedid
best
was
classified asentered
the progression
of disease.
This
patient
not have
tumor
graphical
output.
measurements entered into the database and was therefore not included in the graphical output.

Table 2. Efficacy analyses.
Response

No.

Evaluable for response
Complete Response (CR)
Partial Response (PR)
Stable Disease (SD)
Disease Progression
Unknown *
Disease Control Rate (CR + PR + SD)
Stable Disease > 100 days

0
2
18
14
1
20
12

%
(n = 35)
0
6
51
40
3
57
34

Duration of response, days
Median
Range

263
149–377

Duration of stable disease, days
Median
Range

147
82–426

RECIST 1.1 criteria was used to determine tumor response. * This participant was removed from study after
experiencing an adverse event in cycle 1. There was no post-baseline tumor assessment.
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Figure
2. Examples
of tumor
after glembatumumab
vedotin treatment.
(A) The computerized
Figure
2. Examples
of responses
tumor responses
after glembatumumab
vedotin treatment.
(A) The
tomography
(CT) scan
on the left
target
in the
liver
parenchyma
that is
computerized
tomography
(CT)indicates
scan on the
the baseline
left indicates
thelesion
baseline
target
lesion
in the liver
pointed
at by an arrow.
CT scan
on theThe
right
thethe
shrinkage
in the target
parenchyma
that is The
pointed
at byimage
an arrow.
CTdemonstrates
scan image on
right demonstrates
thelesion
in the target
lesion
after(B)
glembatumumab
(B) The CT
on lesion
the leftin the
after shrinkage
glembatumumab
vedotin
(GV).
The CT scan onvedotin
the left(GV).
demonstrates
thescan
target
demonstrates
the
target
lesion
in
the
porta
hepatis
lymph
node,
and
the
one
on
the
right
shows
the the
porta hepatis lymph node, and the one on the right shows the changes in the lesion after GV. Though
changes
in
the
lesion
after
GV.
Though
the
lesion
appears
to
have
shrunk
in
size,
the
decrease
in
lesion appears to have shrunk in size, the decrease in the lesion’s short axis was not sufficient the
to meet
lesion’s short axis was not sufficient to meet the response criteria of RECIST 1.1. The target lesion
the response
criteria of RECIST 1.1. The target lesion response in the right panel was classified as a
response in the right panel was classified as a stable disease.
stable disease.
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Table 2. Efficacy analyses.

The median overall survival (Figure 3) for the evaluable population was 11.9 months (95% CI: 9.0–16.9).
The median overall survival (Figure
3) for the evaluable population
was 11.9 months (95% CI:
Response
%
The median progression-free survival was
3.1 months (95%No.
CI: 1.5–5.6).
The range of OS was
9.0–16.9). The median progression-free
survival
was
3.1
months
(95%
CI:
1.5–5.6). The range of OS
Evaluable for response
(n = 35)
0.5–40.2
months,
whereas
the
PFS
ranged
from
0.5
to
30.5
months.
was 0.5–40.2 months, whereas the PFS ranged from 0.5 to 30.5 months.
Complete Response (CR)
Partial Response (PR)
Stable Disease (SD)
Disease Progression
Unknown *
Disease Control Rate (CR + PR + SD)
Stable Disease > 100 days
Duration of response, days
Median
Range
Duration of stable disease, days
Median
Range

0
2
18
14
1
20
12

0
6
51
40
3
57
34

263
149–377
147
82–426

RECIST 1.1 criteria was used to determine tumor response. * This participant was removed from study
after experiencing an adverse event in cycle 1. There was no post-baseline tumor assessment.
3. Kaplan–Meier
plots
overallsurvival
survival (A)
(A) and
and progression-free
survival
(B) (B)
in evaluable
FigureFigure
3. Kaplan–Meier
plots
of of
overall
progression-free
survival
in evaluable
patient
population.
The
median
overall
survival
was
11.9
months
(95%
CI:
9.0–16.9)
ranging
between
patient population. The median overall survival was 11.9 months (95% CI: 9.0–16.9) ranging
between
0.5
and
40.2
months.
The
median
progression-free
survival
(PFS)
was
3.1
months
(95%
CI:
1.5–5.6) and
0.5 and 40.2 months. The median progression-free survival (PFS) was 3.1 months (95% CI: 1.5–5.6)
and ranged between 0.5 and 30.5 months.
ranged between 0.5 and 30.5 months.

4.3. Adverse Events
All 35 patients who received GV were evaluable for toxicity. Common treatment-related adverse
events (TRAEs) are presented as groups by organ class in CTCAE grades (Table 3). The most common
TRAEs were skin and subcutaneous AEs, namely alopecia (80%), maculopapular rash (54%), and
pruritus (51%), as well as (less frequently) dry skin (9%), skin hypopigmentation (9%), and acneiform
rash (6%). Leukopenia (69%), neutropenia (60%), anemia (40%), lymphopenia (17%), and
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4.3. Adverse Events
All 35 patients who received GV were evaluable for toxicity. Common treatment-related adverse
events (TRAEs) are presented as groups by organ class in CTCAE grades (Table 3). The most
common TRAEs were skin and subcutaneous AEs, namely alopecia (80%), maculopapular rash
(54%), and pruritus (51%), as well as (less frequently) dry skin (9%), skin hypopigmentation (9%),
and acneiform rash (6%). Leukopenia (69%), neutropenia (60%), anemia (40%), lymphopenia (17%),
and thrombocytopenia (14%) were the most common hematologic AEs; meanwhile, elevated alanine
aminotransferase/aspartate aminotransferase (ALT/AST) (63%), nausea (51%), diarrhea (31%), elevated
alkaline phosphatase (26%), constipation (23%), oral mucositis (17%), and vomiting (14%) were the most
common gastrointestinal TRAEs. Other common TRAEs were fatigue (57%), peripheral neuropathy
(43%), anorexia (37%), and arthralgia (26%). The most common grade 3/4 AE was neutropenia (48%),
which was reversible and managed with the use of GM-CSF in subsequent cycles. Other grade 3/4 AEs
occurring in 1–2 (3–6%) patients were leukopenia, elevated ALT/AST, nausea, diarrhea, constipation,
vomiting, rash, fatigue, weight loss, hyponatremia, hypophosphatemia, and hypotension. There was
only one grade 5 TRAE reported as encephalopathy, which resulted in death during the first treatment
cycle. Upon further review of the data entry, this death was noted as disease progression in the liver
with resultant hepatic encephalopathy, and it was not clearly related to GV. Twenty-seven serious
adverse events (SAEs) were reported to the serious adverse event portal. Among these SAEs, three (9%)
events of neutropenia; two (6%) events of hyponatremia, vomiting, and maculopapular rash; and one
(3%) event of elevated AST, diarrhea, hypotension, abdominal pain, nausea, constipation were reported
as grade 3 SAEs. The reported grade 4 SAEs comprised seven (20%) cases neutropenia, one (3%) case
of leukopenia, and one (3%) case acute kidney injury. There was only one (3%) grade 5 SAE with
encephalopathy, as detailed above.
Table 3. Treatment-related adverse events.
Adverse Event

Any Severity

CTCAE Grade 3

CTCAE Grade 4
No.

%

1
5

3
14

No.

%

No.

%

Hematologic
Leukopenia
Neutropenia
Anemia
Lymphopenia
Thrombocytopenia

24
21
14
6
5

69
60
40
17
14

1
12

3
34

Gastrointestinal
Elevated ALT/AST
Nausea
Diarrhea
Elevated ALP
Constipation
Mucositis, oral
Vomiting
Hyperbilirubinemia
Abdominal pain
Dry mouth
Dyspepsia
Oral pain

22
18
11
9
8
6
5
4
2
2
2
2

63
51
31
26
23
17
14
11
6
6
6
6

1
1
1

3
3
3

1

3

2

6
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Table 3. Cont.
Adverse Event

Any Severity
No.

%

Skin and Subcutaneous
Alopecia
Rash, maculopapular
Pruritus
Dry skin
Skin hypopigmentation
Rash, acneiform

28
19
18
3
3
2

80
54
51
9
9
6

General
Fatigue
Pain
Chills
Flu like symptoms
Localized edema
Weight loss

20
6
2
2
2
2

57
17
6
6
6
6

Nervous System
Peripheral Neuropathy
Dysgeusia
Headache
Dizziness

15
8
3
2

43
23
9
6

Arthralgia
Myalgia
Pain in extremity
Generalized muscle weakness

9
6
3
2

26
17
9
6

Respiratory
Dyspnea

5

14

Renal and Electrolytes
Hyponatremia
Hypophosphatemia
Hypokalemia
Hyperkalemia

5
4
3
2

14
11
9
6

Metabolism and Nutrition
Anorexia
Hypoalbuminemia
Hyperglycemia

13
3
2

37
9
6

Vascular
Hot flashes
Hypotension

3
3

9
9

CTCAE Grade 3

CTCAE Grade 4

No.

%

No.

2

6

1

3

1

3

2
1

6
3

1

3

%

Musculoskeletal

Abbreviations: CTCAE: Common Terminology Criteria for Adverse Events, ALT: alanine aminotransferase,
AST: aspartate aminotransferase, ALP: alkaline phosphatase. The treatment-related AEs had overall incidences
≥3%, and all had grade 3–4 severity. Only one patient had a grade 5 treatment-related AE with encephalopathy.
Empty data represent no reported toxicity.

Only one of the responders developed rash during the first cycle of the treatment, but it should
be noted that rash occurring in cycle one did not correlate with response or PFS, as demonstrated in
previous studies [18,19].
4.4. Gpnmb Tissue Expression
Of the 32 patients, 26 (81%) had tissues available for baseline, and 24 (75%) had tissues available
for GPNMB expression after one cycle of treatment. In baseline tissue, GPNMB was highly expressed
across all metastatic tissues, with 11 (42%) out of 26 available tissues demonstrating expression in 100%
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of tumor cells, whereas 8 (31%) of 26 tissues exhibited expression in 20–95% of tumor cells. Seven (27%)
of the baseline tissues did not demonstrate GPNMB expression. In the evaluation after one cycle of GV
(Table S1), 8 (33%) out of 24 available tissues demonstrated expression in 100% of tumor cells, and two
(8%) of them demonstrated zero expression in tumor cells, all unchanged from baseline. While nine
(38%) tumor samples showed paradoxical increases in GPNMB expression, three (13%) had a decreased
expression from baseline. Two patients (8%) did not have a baseline tissue available to compare.
5. Discussion
This phase II trial of GV was conducted to evaluate its safety and efficacy in patients with
metastatic uveal melanoma. The best objective response rate was 6%, with no CR. However, there were
56% of patients with an SD, most of whom had an SD > 100 days. The median PFS was 3.1 months,
and the median OS was 11.9 months. The side effect profile was tolerable with grade 3–4 neutropenia
occurring in 56% managed with GM-CSF.
The objective response rate to GV was not very improved compared to immunotherapy with PD-1
and PD-L1 antibodies (3.6%) [7] or targeted therapy with selumetinib and dacarbazine (3%) [20].
The median PFS in this study was higher than what has been seen in past studies with checkpoint
blockade and targeted therapy [5,7,20]. A median OS of 11.9 months was likewise improved over
past metastatic trials for this patient population. However, this is still a minimal improvement over
historical cohorts and patients who only opt for the best supportive care [21].
The toxicities seen in this study have been previously reported in both cutaneous melanoma and
triple-negative breast cancer [18,19]. Unlike those studies, the development of a rash in cycle 1 did
not emerge as a biomarker for the response or clinical benefit. Elevated liver transaminases were
likely higher in this study due to the common presence of hepatic metastases in uveal melanoma and,
therefore, in our study population (91%).
The baseline expression of GPNMB (73%) appeared to be lower than the previous work of Williams
et al. that demonstrated an 86% expression of GPNMB in primary uveal melanoma tissues [12]. In breast
and cutaneous melanoma, the expression of GPNMB is far lower, and GPNMB expression has been
observed to be stable over time [19]. However, we observed a paradoxical increase in expression
of GPNMB in 38% of the tumor tissues after one cycle of GV treatment. This raises the possibility
of inadequate target saturation by GV at a dose of 1.9 mg/kg in this disease population with a high
percentage and intensity of GPNMB staining per tumor. Alternative mechanisms may be at play, thus
leading to the upregulation of target.
The results of the study should be assessed within its limitations. First, this study had a small
sample size. A current lack of standard treatment modalities for metastatic uveal melanoma makes
it challenging to compare treatment efficacy. However, we compared the efficacy of GV to the best
available efficacies amongst the clinical trials completed in the past. Though we had a high number of
tumor tissue evaluated, the baseline and/or post-treatment tissue samples of some of the patients were
not available for GPNMB expression.
6. Conclusions
In summary, GV was well-tolerated in the metastatic uveal melanoma patient population.
The disease control rate was high and sustained despite a low objective response rate. Combination
treatment strategies with immune checkpoint inhibitors are of interest, as are antibody–drug conjugates
against other possible uveal melanoma targets.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/8/2270/s1,
Table S1: Pre and post treatment GPNMB expression.
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